COVID-19: 4,400 adverse events reported after receiving Pfizer, BioNTech vaccine in US

Among those, 175 case reports were identified for further review as possible cases of severe allergic reaction, including anaphylaxis.

Published On 2021-01-07 05:07 GMT   |   Update On 2021-01-07 07:44 GMT

Washington: Nearly 4,400 adverse events were reported after people received the Pfizer-BioNTech Covid-19 vaccine in the US, with 21 cases determined to be anaphylaxis, according to a report by the Centers for Disease Control and Prevention (CDC).

The US Food and Drug Administration issued an Emergency Use Authorization for Pfizer-BioNTech Covid-19 vaccine on December 11, 2020, administered as two doses separated by 21 days, reports Xinhua news agency.

As of December 23, 2020, a total of 1,893,360 first doses of Pfizer-BioNTech COVID-19 vaccine had been administered in the US, according to the CDC report.

Reports of 4,393 adverse events had been submitted to the Vaccine Adverse Event Reporting System in the country.

Among those, 175 case reports were identified for further review as possible cases of severe allergic reaction, including anaphylaxis.

Twenty-one cases were determined to be anaphylaxis, including 17 in persons with a documented history of allergies or allergic reactions, seven of whom had a history of anaphylaxis, according to the CDC.

Anaphylaxis is a life-threatening allergic reaction that does occur rarely after vaccination, with onset typically within minutes to hours, said the CDC.

Read also: Pfizer COVID-19 vaccine approved by Colombian regulator for emergency use

Locations administering Covid-19 vaccines should adhere to CDC guidance for use of the jabs, including screening recipients for contraindications and precautions, having the necessary supplies available to manage anaphylaxis, implementing the recommended post-vaccination observation periods, and immediately treating suspected cases of anaphylaxis with intramuscular injection of epinephrine, said the CDC.

Read also: New use of Pfizer vaccine increasing doses by 20 percent may soon get EU go ahead: Report



Tags:    
Article Source : IANS

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News